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Background/Aims: The cumulative surgery rate and post-
operative relapse of intestinal Behçet’s disease (BD) have 
been reported to be high. This study aimed to establish a 
scoring system based on follow-up endoscopic findings that 
can predict intestinal BD recurrence after surgery. Methods: 
Fifty-four patients with intestinal BD who underwent surgery 
due to bowel complications and underwent follow-up colo-
noscopy were retrospectively investigated. Their clinical data, 
including colonoscopic findings, were retrieved. Classifica-
tion and regression tree analysis was used to develop an 
appropriate endoscopic classification model that can explain 
the postsurgical recurrence of intestinal BD most accurately 
based on the following classification: e0, no lesions; e1, soli-
tary ulcer <20 mm in size; e2, solitary ulcer ≥20 mm in size; 
and e3, multiple ulcers regardless of size. Results: Clinical 
relapse occurred in 37 patients (68.5%). Among 38 patients 
with colonoscopic recurrence, only 29 patients had clinically 
relapsed. Multivariate analysis identified higher disease 
activity index for intestinal BD at colonoscopy (hazard ratio 
[HR], 1.013; 95% confidence interval [CI], 1.005 to 1.021; 
p=0.002) and colonoscopic recurrence (HR, 2.829; 95% CI, 
1.223 to 6.545; p=0.015) as independent risk factors for 
clinical relapse of intestinal BD. Endoscopic findings were 
classified into four groups, and multivariate analysis showed 
that the endoscopic score was an independent risk factor 
of clinical relapse (p=0.012). The risk of clinical relapse was 
higher in the e3 group compared to the e0 group (HR, 6.284; 
95% CI, 2.036 to 19.391; p=0.001). Conclusions: This new 
endoscopic scoring system could predict clinical relapse in 
patients after surgical resection of intestinal BD. (Gut Liver 
2018;12:674-681)
Key Words: Behcet syndrome; Postoperative care; Recur-
rence; Endoscopy
INTRODUCTION
Behçet’s disease (BD) is a multisystemic vasculitic disorder 
featuring multi-organ involvement including the gastrointesti-
nal tract.1,2 According to the current criteria, “intestinal BD” can 
be diagnosed if there is a typical oval-shaped large ulcer in the 
terminal ileum or inflammation in the small or large intestine 
with clinical findings meeting the diagnostic criteria of BD.3,4 
The clinical disease course of intestinal BD may be difficult to 
predict, as it can range from quiescent disease to chronic refrac-
tory disease that can result in complications such as intestinal 
perforation, fistula, or massive intestinal bleeding, eventually 
requiring surgical treatment.5 Ulcers in intestinal BD tend to 
perforate at multiple sites and since optimal treatment strategies 
remain largely unknown, surgery is often performed for patients 
unresponsive to medical treatments or those with bowel com-
plications.6 More importantly, clinical recurrence of intestinal 
BD after bowel resection is frequent, as reported by our previous 
studies; cumulative surgery rates of intestinal BD were 6.7% 
and 15.1% at 2 and 5 years after diagnosis, respectively, and the 
recurrence rate of intestinal lesions was approximately 50% at 
2 years postoperatively.7 However, demographic or clinical risk 
factors and endoscopic findings at follow-up that are highly 
predictive of postoperative recurrence or recrudescence of 
symptomatic intestinal BD have not yet been clearly identified. 
Endoscopic recurrence correlates with the subsequent de-
velopment of clinical recurrence as well as the development of 
complications and need for reoperation. Since endoscopic find-
ings such as a typically shaped ulcer in the ileocecal region or 
at the anastomotic site are critical for diagnosis along with de-
fining recurrence of intestinal BD,3,4 a regular follow-up endos-
copy is essential after intestinal surgery. Rutgeerts et al.8 have 
developed an endoscopic scoring system for Crohn’s disease (CD) 
that is classified by the number and distribution of ulcerations 
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at follow-up endoscopy and can predict postoperative recur-
rence of CD. Moreover, Schwartz and Regueiro9 have suggested 
a treatment algorithm which outlines management approaches 
based on the risk of recurrence in CD. However, there are no 
reports of an endoscopic scoring system or treatment algorithm 
after surgery in intestinal BD.
Therefore, this study aimed to develop an appropriate scoring 
system using follow-up endoscopic findings which can predict 
recurrence of intestinal BD after intestinal resection.
MATERIALS AND METHODS
1. Study subjects and diagnostic criteria
Intestinal BD patients who underwent surgical intervention 
due to refractoriness to medical treatment or development of 
complications from intestinal BD at Severance Hospital, Yonsei 
University College of Medicine, Seoul, Korea, between March 
1986 and December 2015 were retrospectively identified. Intes-
tinal BD was diagnosed according to established criteria based 
on colonoscopic features and clinical manifestations.3,4 Patients 
classified as ‘‘definite,’’ ‘‘probable,’’ and ‘‘suspected’’ were in-
cluded in the study. We excluded suspected patients with any 
evidence of another gastrointestinal disease such as CD, intesti-
nal tuberculosis, or ischemic colitis during the follow-up period. 
2. Clinical evaluations and definition of variables
The patient medical records were reviewed by two physicians 
(J.H.C. and J.W.P.). Among them, 54 patients who underwent 
at least one follow-up endoscopy within 5 years after surgery 
were selected, regardless of clinical relapse. After selection, 
demographic and preoperative clinical data including age at 
diagnosis, prior abdominal surgical history due to intestinal BD, 
gastrointestinal symptoms at diagnosis, and disease activity 
index prior to surgery and at the time of follow-up colonoscopy 
were retrieved. Systemic manifestations, clinical BD subtypes, 
follow-up colonoscopic findings (ulcer location, distribution, 
shape, number, and depth) and history of perioperative drug 
usage were retrieved. Since there are very limited medication 
options for intestinal BD, clinicians usually maintain previous 
medications used before surgery even after the bowel resection. 
The term “perioperative” is used for this reason. We also evalu-
ated laboratory results including leukocyte counts, hemoglobin 
level, erythrocyte sedimentation rate, C-reactive protein level, 
and albumin level at the time of follow-up colonoscopy. 
We measured intestinal BD activity using the disease activ-
ity index for intestinal BD (DAIBD). The DAIBD provides a total 
score drawn from eight variables (general well-being, fever, ex-
tra-intestinal manifestations, abdominal pain, abdominal mass, 
abdominal tenderness, intestinal complications, and number of 
liquid stools), with a higher score reflecting greater disease ac-
tivity. Patients with DAIBD scores <19, 20–39, 40–74, and ≥75 
were considered to have remission, mild, moderate, and severe 
disease activities, respectively.10 Clinical relapse was defined 
as DAIBD ≥40, existence of newly added medications, admis-
sion due to symptomatic aggravation, or re-operation related 
to intestinal BD. As for the colonoscopy findings, the location, 
shape (oval, geographic, or volcano type), distribution (localized 
or diffuse), number, depth (aphthous, shallow or deep) and size 
(<10 mm, 10 to 20 mm or ≥20 mm) of intestinal ulcers were 
described. If any newly developed ulcer was found in postop-
erative bowel analysis, the patient was considered to have en-
doscopically recurrent disease. Symptomatic relapse was defined 
when the patient expressed an intestinal symptom or symptoms 
at the time of follow-up colonoscopy.
This study was approved by the Institutional Review Board of 
Severance Hospital, Seoul, Korea (IRB number: 4-2017-2022).
3. Statistical analysis
The software program SPSS version 21.0 (IBM Corp., Ar-
monk, NY, USA) was used for statistical analyses. Student t-test 
or the Mann-Whitney U-test was used to compare numerical 
variables between groups. The chi-square or Fisher exact test 
was used to compare categorical variables. p-values<0.05 were 
considered statistically significant. Classification and regression 
tree (CART) analysis11,12 was used to determine an appropriate 
model of endoscopic classification which can explain the post-
surgical recurrence of intestinal BD most accurately.
CART is a decision tree algorithm developed by Breiman et 
al.11 in 1984. CART algorithm can be used for building both 
“classification” and “regression” decision trees. The impurity 
(or purity) measure used in building decision tree in CART is 
“Gini Index.” In this tree building, choosing the best splitter is 
to minimize the average “impurity” of the two-child nodes and 
based on this, the first split must be whether colonoscopic re-
currence has occurred or not. After that, the second split could 
be any other factor; however, depth and size could be correlated 
as larger ulcer is mostly deeper in depth. For this reason, we 
selected the size factor rather than the depth factor, which could 
be more objective. Shape of the recurred ulcer was another im-
portant factor, but in most cases, they were oval-shaped. Only 
two cases had volcano-shaped ulcer and we decided that this 
could not result in accurate analysis, for the total case number 
was small (54 cases). Accordingly, factors left are the number 
and size of ulceration. Derived from Gini Index, best tree re-
sulted in the second and third split to be the number and then 
the size of ulcer. This resulted in the new following endoscopic 
scoring model; e0, no lesions; e1, <20 mm sized solitary ulcer; 
e2, ≥20 mm sized solitary ulcer; and e3, multiple ulcers regard-
less of size.
We also constructed multivariate Cox regression models to 
identify independent factors associated with severe clinical dis-
ease course. Adjusted odds ratios and 95% confidence intervals 
(CIs) were calculated.
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RESULTS
1. Baseline clinical and endoscopic characteristics of pa-
tients with intestinal BD 
A total of 91 intestinal BD patients who underwent surgi-
cal intervention due to intestinal BD were identified. Thirty-six 
patients were excluded due to incomplete data because of lack 
of colonoscopic or clinical data. One patient was excluded due 
to follow-up loss. The remaining 54 patients were eligible for 
this study with 28 male and 26 female patients. Clinical disease 
relapse occurred in 37 patients (68.5%) and of these, 16 patients 
(29.6%) underwent re-operation. Thirty-eight patients (70.37%) 
had colonoscopic recurrence at follow-up colonoscopy and of 
these, only 29 had clinical relapse. 
Clinical characteristics and demographics of patients are listed 
in Table 1. The median age at diagnosis was 36 years (range, 
12 to 64 years) and median disease duration was 126.5 months 
(range, 21 to 432 months). Thirty-seven patients (68.5%) were 
complete type of intestinal BD and most of them had recurrent 
oral ulcer (64.8%). Twenty-two (40.7%) had history of at least 
one time of intestinal resection before the last surgery. Thirty-
one (57.4%) were using immunomodulators before surgery and 
87.0% of total patients were on systemic steroids. The mean 
DAIBD score before surgery was checked as 121.67 (±34.29), but 
was decreased to 45.74 (±36.90) after surgery. The endoscopic 
characteristics at follow-up colonoscopy are listed in Table 2. 
All colonoscopically recurred cases had ulcers located in the 
anastomosis site and 35 cases (92.1%) occurred in the localized 
area. Regarding the depth and appearance of intestinal ulcers, 
12 patients (31.6%) had well-demarcated deep ulcers considered 
typical of intestinal BD, 26 patients (68.4%) had oval-shaped 
ulcers, 10 patients (26.3%) had geographic ulcers, and two pa-
tients (5.3%) had volcano-type ulcers. 
2. Risk factors for clinical relapse after surgery in intestinal 
BD patients
The main aim of this study was to establish an appropriate 
scoring system using follow-up endoscopic findings that can 
predict clinical recurrence after surgical resection of an affected 
bowel in intestinal BD patients. Therefore, Kaplan-Meier curves 
were constructed to compare relapse-free survival of patients 
classified by clinical and endoscopic factors including colono-
scopic recurrence. Based on this analysis, only colonoscopic re-
currence was associated with the development of clinical relapse 
(hazard ratio [HR], 2.829; 95% CI, 1.223 to 6.545; p=0.015) (Fig. 
Table 1. Comparison of Baseline Characteristics of Two Groups Ac-




Age at diagnosis, yr  36 (12–64)
Male sex 28 (51.9)
Disease duration, mo 126.5 (21–432)
Clinical subtype
   Complete 37 (68.5)
   Incomplete 17 (31.5)
   Suspected 0
Systemic symptoms and signs of BD at surgery
   Recurrent oral ulcer 35 (64.8)
   Recurrent genital ulcer 15 (27.8)
   Ocular lesion 3 (5.5)
   Skin lesion 15 (27.8)
   Positive pathergy test 1 (1.8)
   Arthritis or arthralgia 14 (25.9)
   Neurologic lesion 0 
   Vascular lesion 0
History of previous abdominal surgery 22 (40.7)
Medication history before surgery
   Immunomodulator 31 (57.4)
   Anti-TNF-α antibody 2 (3.7)
   Corticosteroid 47 (87.0)
Disease activity index for intestinal  
  BD at surgery
121.67±34.29
Disease activity index for intestinal  
  BD at follow-up
45.74±36.90
Symptomatic relapse 30 (55.6)
Colonoscopic recurrence 38 (70.4)
Data are presented as median (range) or number (%).
BD, Behçet’s disease; TNF, tumor necrosis factor.
Table 2. Colonoscopic Findings in 38 Intestinal Behçet’s Disease Pa-
tients with Colonoscopic Recurrence
No. (%)
Site of recurrence 
   Anastomosis site 38 (100.0)
   Other site 0 
Distribution 
   Localized 35 (92.1)
   Diffuse 3 (7.9)
Depth
   Aphthous 9 (23.7)
   Shallow 17 (44.7)
   Deep 12 (31.6)
Shape
   Oval 26 (68.4)
   Geographic 10 (26.3)
   Volcano 2 (5.3)
Size, mm
   <20 25 (65.8)
   ≥20 13 (34.2)
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1A). Younger age at diagnosis (≤35 years), history of immuno-
modulator or perioperative anti-tumor necrosis factor-α (anti-
TNF-α) antibody usage were not associated with the develop-
ment of clinical relapse (Fig. 1B-D). 
Univariate and multivariate Cox regression analysis adjusting 
for age at diagnosis, sex and disease duration were performed. 
This identified two independent risk factors associated with clini-
cal relapse; higher DAIBD at colonoscopy (HR, 1.013; 95% CI, 
1.005 to 1.021; p=0.002) and colonoscopic recurrence (HR, 2.829; 
95% CI, 1.223 to 6.545; p=0.015) were independent risk factors 
for clinical relapse in intestinal BD (Table 3). Perioperative immu-
nomodulator usage did not affect clinical relapse, as well as peri-
operative steroids or anti-TNF-α antibody usage. Total follow-up 
duration was median 26.5 months (range, 1 to 165 months).
We performed another multivariate analysis to determine 
which colonoscopic findings of recurred ulceration were associ-
ated with clinical relapse (Table 4). The number of ulcerations, 
whether solitary or multiple, was significantly associated with 
clinical relapse (HR, 2.884; 95% CI, 1.038 to 8.013; p=0.042). The 
size of the recurred ulceration also showed a relation to higher 










































































































































































































































Fig. 1. Clinical relapse-free survival rate during long-term follow-up in intestinal Behçet’s disease patients grouped according to clinical factors 
colonoscopic recurrence (A), age at diagnosis (B), perioperative immunomodulator usage (C), perioperative anti-tumor necrosis factor-α antibody 
usage (D).
HR, hazard ratio; CI, confidence interval. 
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3. Development of an endoscopic scoring system to predict 
relapse after surgery in intestinal BD patients
Endoscopic findings needed to be classified properly to de-
termine an appropriate model to best predict postsurgical recur-
rence of intestinal BD. Hence, we used the CART analysis (Fig. 2). 
Among 54 patients, 38 patients showed colonoscopic findings 
at follow-up which implied recurrence and were classified into 
another two groups based on the number of ulcerations: mul-
tiple (n=15) versus solitary (n=23). Fifteen patients had multiple 
ulcerations and of these, 12 patients (80.0%) were clinically 
relapsed. Twenty-three patients with solitary ulcers were divided 
into the next two groups by size of ulceration: shorter than 20 
mm in diameter (n=13) versus 20 mm or longer in diameter 
(n=10). Patients with small ulcers had a lower relapse rate (9/13, 
69.2%), while patients with a larger ulcer had a higher relapse 
rate (8/10, 80.0%). Based on this result, endoscopic findings 
were classified into four groups according to the size and num-
ber of recurred ulcer(s); e0, no lesions; e1, <20 mm sized solitary 
ulcer; e2, ≥20 mm sized solitary ulcer; and e3, multiple ulcers 
regardless of size. 
Multivariate analysis adjusting for sex, age at diagnosis, dis-
ease duration, previous surgical resection, perioperative medica-
tion usage and disease activity score showed that the endoscopic 
score was an independent risk factor of clinical relapse (p=0.012). 
The risk of clinical relapse was approximately 6 times higher in 
the e3 colonoscopy group compared to the e0 group (HR, 6.284; 
95% CI, 2.036 to 19.391; p=0.001) (Fig. 3). The e2 group (HR, 
1.953; 95% CI, 0.545 to 6.997; p=0.304) and the e1 group (HR, 
1.672; 95% CI, 0.519 to 5.39; p=0.389) also showed numerically 
higher risk of clinical relapse than the e0 group, while it did not 
show any statistical significance. 
DISCUSSION
Intestinal BD is characterized by deep ulcers, which are most 
commonly located in the terminal ileum or the ileocecal region 
and tend to perforate or penetrate the intestinal wall.13,14 There-
fore, a considerable number of patients with intestinal BD even-
tually require emergency or elective operations and likewise, pa-
tients who have little or no response to medical treatment often 
undergo surgical intervention.6,15 This disease is also well known 
for a high risk of early recurrence after intestinal resection.16-18 
Previous studies including ours showed that the recurrence rate 
of intestinal lesions was over 50% at 2 years postoperatively 
and as high as 75% in one study.7,19 To our knowledge, there are 
few preceding studies investigating the prediction of postopera-
tive recurrence of intestinal BD. Furthermore, there have been 
no studies on the development of an objective endoscopic scor-
ing system to predict the postoperative recurrence of intestinal 
BD. Our current study is the first to present an actual endoscopic 
scoring system to predict clinical relapse of intestinal BD. 
Rutgeerts et al.8 developed an endoscopic scoring system re-
lated to the postoperative recurrence of CD. This was a prospec-
tive endoscopic cohort study which demonstrated that the post-
operative clinical course of CD is best predicted by the severity 
of endoscopic lesions of CD during the first year after resection. 
They also examined the natural history of CD recurrence in 
other studies, which consistently showed that the severity of 
endoscopic recurrence at 1 year is predictive of earlier clinical 
relapse. These studies regarding endoscopic prediction of post-
operative recurrence prompted numerous sequential studies.
Similarly, in this study, we compared five colonoscopic pa-
Table 3. Cox Hazard Regression Analysis of Risk Factors for Clinical Relapse after Intestinal Resection 
Crude OR (95% CI) p-value Adjusted OR (95% CI)* p-value
DAIBD at initial diagnosis 1.003 (0.993–1.013) 0.549 1.001 (0.991–1.011) 0.904
DAIBD at follow-up colonoscopy 1.006 (0.999–1.013) 0.073 1.013 (1.005–1.021) 0.002
Perioperative immunomodulator use (no vs yes) 1.051 (0.526–2.102) 0.887 1.171 (0.563–2.437) 0.673
Perioperative anti-TNF-α antibody use (no vs yes) 1.565 (0.702–3.489) 0.274 1.988 (0.866–4.565) 0.105
Perioperative steroid use (no vs yes) 1.196 (0.415–3.442) 0.741 2.453 (0.742–8.111) 0.141
Colonoscopic recurrence (no vs yes) 1.747 (0.795–3.848) 0.165 2.829 (1.223–6.545) 0.015
OR, odds ratio; CI, confidence interval; DAIBD, disease activity index for intestinal Behçet’s disease; TNF, tumor necrotic factor.
*Adjusted for sex, age at diagnosis, disease duration.
Table 4. Multivariate Cox Hazard Regression Analysis of Colono-
scopic Findings for Clinical Relapse after Intestinal Resection
HR (95% CI) p-value
Ulcer description
   Location (ileocecal area vs others) 0.908 (0.208–3.96) 0.898
   Distribution (localized vs diffuse) 0.553 (0.116–2.643) 0.458
   Depth 0.507
      Aphthous vs shallow 1.500 (0.484–4.643) 0.482
      Aphthous vs deep 0.464 (0.042–5.134) 0.531
   Shape 0.184
      Oval vs geographic 0.369 (0.125–1.096) 0.073
      Oval vs volcano 0.678 (0.083–5.545) 0.717
Size (≤20 mm vs >20 mm) 5.030 (0.469–53.914) 0.182
Number (solitary vs multiple) 2.884 (1.038–8.013) 0.042
HR, hazard ratio; CI, confidence interval.
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rameters and adopted the CART method12 as an alternative to 
generate a simpler and easier scoring system than the diagnostic 
tools derived from logistic regression. The CART method identi-
fied the number and size of ulcers as the most distinguishable 
features. By the sequential application of these two variables, 
with ulcer number followed by lesion size, we developed a nov-
el endoscopic scoring system composed of four categories. As 
demonstrated by our results, an endoscopic score of “e3” which 
represented the group with multiple ulcers regardless of size, 
had a 6.284 higher chance of recurrence than the group with no 
lesions. This result suggests an applicable parameter which can 
be useful to foresee the postoperative clinical recurrence of in-
testinal BD, and can also possibly be used to develop a strategy 
for future treatment of recurrent intestinal BD after bowel resec-
tion surgery. 
Interestingly, a similar result was obtained in the separate 
multivariate analysis of endoscopic features of recurred ulcers–
the number of ulcerations, whether solitary or multiple, was 
significantly associated with clinical relapse (HR, 2.884; 95% CI, 
1.038 to 8.013; p=0.042) which is a novel finding. According 
to other previous studies including ours, volcano-shaped ulcers 
were usually identified as an independent predictive factor for 
poor prognosis and recurrence.7,19-21 Kim et al.22 indicated that 
volcano-type ulcerations in intestinal BD demonstrated a sig-
nificantly lower remission rate with medical treatment, higher 
cumulative surgery rate, and higher recurrence rate. Jung et 
al.20 reported that volcano-type ulcers are also predictive factors 
for recurrence and reoperation in patients treated surgically. 
These findings may explain the high surgery rate of intestinal 
BD patients, along with another study which demonstrated that 
patients with volcano-shaped ulcers have an increased risk of 
free bowel perforation.23 On the other hand, there was one Japa-
nese study reporting that the number of ulcerations was related 
to recurrence, relapse and perforation.15 Why multiplicity of a 
Colonoscopic recurrence
n=16 (8 relapsed) n=38 (29 relapsed)A
<20 mm (n=13, 9 relapsed) >20 mm (n=10, 8 relapsed)B C
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Fig. 3. Actuarial analysis of clinical relapse in patients stratified ac-
cording to the severity of endoscopic lesions at follow-up endoscopy. 
HR, hazard ratio; CI, confidence interval. Median follow-up period: 
26.5 months (range, 1-165 months). 
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recurrent ulcer is inclined to more frequent clinical relapse is 
still unknown; however, this can be somewhat explained by the 
fact that mucosal healing is significantly associated with clini-
cal courses of various inflammatory bowel diseases. Since Rut-
geerts et al.24 proposed to focus on mucosal healing and disease 
course as primary outcome measures, studies regarding mucosal 
healing and prognosis of inflammatory bowel diseases have 
been consistently accumulating. A Norwegian study reported 
that mucosal healing after 1 year of treatment is predictive of 
reduced subsequent disease activity and decreased need for ac-
tive treatment.25 Moreover, one of our studies also demonstrated 
that mucosal healing is an independent factor predictive of the 
long-term prognosis of intestinal BD.26 From these data, we can 
carefully conjecture that the amount of defected mucosa might 
be associated with a higher recurrence rate and worse prognosis, 
so patients with multiple ulcers might be more prone to clinical 
relapse compared to patients with a solitary ulcer. These results 
not only give further strength to the use of mucosal healing as 
a clinical indicator and treatment goal in intestinal BD, but also 
suggest another candidate for future study–the relationship be-
tween total surface area of a mucosal defect and clinical prog-
nosis. 
Our results also showed that a higher DAIBD score at follow-
up colonoscopy was associated with a higher rate of clinical re-
lapse. The DAIBD is composed of eight items. This finding sug-
gests that the DAIBD score should be essential along with the 
colonoscopic scoring system in creating a treatment algorithm 
to predict recurrent intestinal BD.
In our study, all cases of the recurrent ulcers were noted at 
the anastomotic site and were mostly localized. Furthermore, the 
median relapse-free survival was 14 months and ranged from 
1 to 147 months. Jung et al.20 also reported that the cumulative 
recurrence rate after surgical treatment was 29.2% at 2 years 
and 47.2% at 5 years. Therefore, it is suggested that in patients 
with intestinal BD who undergo surgery, follow-up examina-
tions with radiography and endoscopy should begin before 2 
years postoperatively with careful focus on the anastomotic site.
This study has several limitations. First, the number of pa-
tients was insufficient to reach a decisive conclusion, even 
though our study results were statistically eligible. Accordingly, 
this system should be validated in a larger scale, prospective 
cohort. Second, we retrospectively analyzed clinical and colo-
noscopic characteristics and postoperative follow-up outcomes 
when determining the likelihood of clinical relapse. Moreover, 
follow-up endoscopies were performed at different time points 
after surgery.
In conclusion, this new endoscopic scoring system might help 
predict clinical relapse in patients undergoing surgical resection 
of intestinal BD. Furthermore, as stated above, this system could 
be the basis for developing an algorithm concerning the treat-
ment of intestinal BD after surgery. 
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